Dexcom, Inc. (Nasdaq: DXCM) received approval from Health Canada for the Dexcom G7 Continuous Glucose Monitoring System for all types of diabetes, ages two and older. This technology can help manage diabetes more effectively and has been shown to reduce hospitalizations and emergency room visits due to hypoglycemia by up to 42%. 

Although approved, the Dexcom G7 is not yet available for purchase, but Dexcom Canada aims to make it accessible to Canadians with diabetes by the end of 2023. 

On Monday, $DXCM closed at $127.02, down $1.49 (1.16%)

In other news, Ensysce Biosciences, Inc. (Nasdaq: ENSC), a company specializing in novel drug delivery systems, was initiated for coverage by HC Wainwright & Co. with a Buy rating and a price target of $9.

Based on Monday's closing price of $2.36, the stated price target suggests a potential upside of $6.64 or approximately 281.4% for $ENSC, according to the investment banking firm's perspective.

Genfit S.A. (Nasdaq: GNFT), a biopharmaceutical company focused on metabolic and liver-related diseases, was maintained with a Buy rating by HC Wainwright, who raised the price target from $9 to $11.

With $GNFT closing at $3.74 on Monday, the raised price target indicates a potential upside of $7.26 or approximately 194.1%, based on the financial services firm's analysis.

LifeMD, Inc. (Nasdaq: LFMD), a company specializing in telemedicine and virtual healthcare services, received coverage initiation from HC Wainwright with a Buy rating and a price target of $9.

Despite closing at $4.79 on Monday, the announced price target projects a potential upside of $4.21 or approximately 87.9% for $LFMD, according to the investment firm's view.

These price targets and potential upsides are based on the assessments and views of HC Wainwright & Co., indicating the projected appreciation in stock value according to their analysis and expectations. Investors should carefully consider these opinions while making investment decisions. 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)